Update on the management of hyperuricemia and gout |
| |
Authors: | Pillinger Michael H Keenan Robert T |
| |
Affiliation: | New York Universuty School of Medicine, New York, NY, USA. michael.pillinger@med.nyu.edu |
| |
Abstract: | Gout is the most common inflammatory arthritis in the United States, with more than three million sufferers. Management of gout has changed relatively little in the past 50 years, despite the fact that many gout patients have contraindications to one or more currently available gout therapies. However, recent insights into gout pathophysiology suggest that time is ripe for a change. This article reviews recent updates in the management of gout, including new insights into dietary management that may permit better control of hyuperuricemia. Also reviewed are the biological and clinical data behind newly-developed drugs for gout that are likely to receive serious consideration for FDA approval, and clinical use, in the foreseeable future. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|